Large-scale testing (Phase 3)WithdrawnNCT05206591
What this trial is testing
Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
Who this might be right for
Active Peripheral Spondyloarthritis (pSpA)
Novartis Pharmaceuticals